Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
COVID-19
•
General Rheumatology
What are your recommendations for adjusting rheumatology medications for patients who test positive for COVID?
Is there any new data/experience since
July ACR Clinical Guidance
that has modified your practice?
Related Questions
How do you approach management in patients with adult-onset Still’s disease presenting with active polyarthritis (without macrophage activation syndrome) who remain symptomatic despite prednisone 15 mg/day and methotrexate 25 mg/week?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
What would be the minimum duration of IL-1 therapy you would recommend for chronic pericarditis?
What options are available for patients who require high dose steroids while taking strong CYP4A4 inducers?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
In what clinical situations do you consider azathioprine for treatment of inflammatory arthritis?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
How would you approach management of retroperitoneal fibrosis causing ureteral compression that has already caused irreversible loss of kidney function?